Why Phathom Pharmaceuticals, Inc.’s (PHAT) Stock Is Down 5.87%
As of Friday, October 30, Phathom Pharmaceuticals, Inc.’s PHAT share price has dipped by 5.87%, which has investors questioning if this is right time to buy.Tudor Pop
Stock Evaluator: Phathom Pharmaceuticals, Inc. (PHAT)
Phathom Pharmaceuticals, Inc. PHAT
$5.74
-0.48
-7.72%
October 30, 2026 4:00:00 PM
EST
Volume: 1,618,808
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Commentary & Analysis
Why Phathom Pharmaceuticals, Inc.’s (PHAT) Stock Is Down 16.69%
As of Friday, October 23, Phathom Pharmaceuticals, Inc.’s PHAT share price has dipped by 16.69%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Phathom Pharmaceuticals, Inc.’s (PHAT) Stock Is Down 25.39%
As of Friday, October 23, Phathom Pharmaceuticals, Inc.’s PHAT share price has dipped by 25.39%, which has investors questioning if this is right time to buy.Omar Beirat
Why Phathom Pharmaceuticals, Inc.’s (PHAT) Stock Is Down 5.67%
As of Friday, October 16, Phathom Pharmaceuticals, Inc.’s PHAT share price has dipped by 5.67%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Phathom Pharmaceuticals, Inc.’s (PHAT) Stock Is Up 6.21%
As of Wednesday, October 14, Phathom Pharmaceuticals, Inc.’s PHAT share price has surged by 6.21%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | PHAT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $455.1 | $470.3 | 37% |
|
| Shares Out (Mil) | 84.9 | 43.4 | 59% |
|
| Institutional Ownership | 94.8% | 81.3% | 66% |
|
| Float (Mil) | 65.4 | 46.8 | 53% |
|
| Beta | 0.50 | 0.71 | 28% |
|
| Avg Daily Volume (000s) | 1,997 | 279 | 82% |
|
| Price Change (52-week) |
(57.7%) | 54.1% | 17% |
|
| Growth | PHAT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | (11.4%) | (2.4%) | 28% |
|
| EPS (5yr) | 4.8% | 14.9% | 38 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (30.2%) | (15.1%) | 19% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 5 | |
| Current EPS | $0.099 | ($0.056) | $0.942 | |
| Month Ago EPS | $0.109 | ($0.030) | $1.076 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | $0.122 | ($0.003) | $1.142 | |
| Year/Year Chg | (160.4%) | (98.2%) | (166.7%) | |
| Financials | PHAT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $275 | $335 | 35% |
|
| Net Income (TTM) (Mil) | ($83) | ($11) | 13% |
|
| EPS (TTM) | ($1.023) | ($0.700) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($21) | ($6) | 15% |
|
| Net Cash Flow (TTM) (Mil) | $49 | $4 | 70% |
|
| Long-Term Debt (Q1) (Mil) | $514 | $6 | 59% |
|
| Enterprise Value (Q1) (Mil) | $865 | $493 | 39% |
|
| Valuation | PHAT | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.17 | na |
|
| P/E | na | 17.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.3 | na |
|
| Ratios | PHAT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 80.7% | 69.4% | 89% |
|
| Net Margin | (30.2%) | 3.3% | 14% |
|
| ROA | (28.4%) | (21.8%) | 17% |
|
| ROE | 21.6% | (21.0%) | 81% |
|
| Liabilities to Assets | 200.8% | 31.8% | 99% |
|
| F-Score | 3 | 3 | 18% |
|
Passing Stock Screens
As of 10/30/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Est Rev: Lowest 30 Down
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 2.8% |
| +/- S&P 500: | -4.6 |
FACTOR STRATEGY
Est Rev: Down 5% Screen
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 2.1% |
| +/- S&P 500: | -5.3 |
